Tyligand Bioscience Ltd.

泰励生物有限公司

Clinical-stage biopharmaceutical company discovering and developing cancer therapeutics, including small molecules and ADCs. Core product TSN1611, an oral KRAS G12D inhibitor, is in phase 2 trials in the US and China for non-small cell lung cancer treatment.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Net current liabilities or net liabilities
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Chapter 18A biotech